bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2017: D N O S A J J M A M F J
2016: D

 
  Other news for:
Leukemia
 Resources from HONselect
New Treatment Approved for Deadly Blood Cancer
Acute lymphoblastic leukemia

By Scott Roberts

THURSDAY, Aug. 17, 2017 (HealthDay News) -- The U.S. Food and Drug Adminstration on Thursday approved the anti-cancer drug Besponsa (inotuzumab ozogamicin) to treat B-cell acute lymphoblastic leukemia (ALL).

B-cell ALL is a rapidly growing cancer that occurs when the bone marrow makes too many B-cell lymphocytes, a type of white blood cell. Almost 6,000 people in the United States are likely to be diagnosed with the disease this year, and more than 1,400 are projected to die from it, according to estimates from the U.S. National Cancer Institute.

"For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low," Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in an agency news release. "These patients have few treatments available and today's approval provides a new, targeted treatment option."

Besponsa was evaluated in clinical studies involving 326 people with relapsed or refractory B-cell ALL who had received one or two prior treatments with other medication. More than 35 percent of people evaluated achieved complete remission for about eight months after taking Besponsa, compared with about 17 percent of those who took a different chemotherapy drug.

Common side effects of Besponsa included low blood platelets, low white-blood-cell count, infection, anemia, fatigue and severe bleeding.

The drug's label includes a boxed warning of possible severe liver damage. Pregnant or breast-feeding women shouldn't take Besponsa, the FDA said.

Approval was granted to Pfizer, based in New York City.

More information

To learn more, visit the FDA.

SOURCE: Aug. 17, 2017 press release, U.S. Food and Drug Administration

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=725686

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Therapeutics
Neoplasms
Blood
B-Lymphocytes
Leukemia
Blood Platelets
Bone Marrow
Infection
Adult
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Inicio img Sobre nosotros img Rincón de la prensa img Boletín HON img Mapa del sitio img Política ética img Contactos